US20060241002A1 - Sodium hypochlorite gel composition - Google Patents

Sodium hypochlorite gel composition Download PDF

Info

Publication number
US20060241002A1
US20060241002A1 US11/114,148 US11414805A US2006241002A1 US 20060241002 A1 US20060241002 A1 US 20060241002A1 US 11414805 A US11414805 A US 11414805A US 2006241002 A1 US2006241002 A1 US 2006241002A1
Authority
US
United States
Prior art keywords
composition
viscosity
sodium hypochlorite
solution
enhancing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/114,148
Inventor
Wallace Rogozinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/114,148 priority Critical patent/US20060241002A1/en
Priority to CA2544383A priority patent/CA2544383C/en
Publication of US20060241002A1 publication Critical patent/US20060241002A1/en
Priority to US11/562,691 priority patent/US7622434B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18Liquid substances or solutions comprising solids or dissolved gases
    • A61L2/186Peroxide solutions
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20Halogens; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26Aluminium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0004Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/0066Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/008Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/106Halogens or compounds thereof, e.g. iodine, chlorite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents

Abstract

A gel composition including a sodium hypochlorite solution; at least one viscosity-enhancing agent; and at least one electrolyte is disclosed. Methods of making the composition, methods of disinfecting, and methods of treating are also disclosed.

Description

    FIELD
  • The present invention relates to compositions for disinfecting substrates, including tissue, and methods of disinfection. The inventive gel composition can comprise a sodium hypochlorite solution, at least one viscosity-enhancing agent, and at least one electrolyte.
  • INTRODUCTION
  • Sodium hypochlorite has a long and well developed history of use as an antiseptic and disinfecting agent. In 1915, Henry Dakin published his classic investigations of antiseptics in the treatment of battlefield wounds encountered in World War I. He evaluated the antiseptic qualities of chemical agents including: phenol, salicylic acid, hydrogen peroxide, iodine, mercuric chloride, silver nitrate and sodium hypochlorite. However, Dakin preferred sodium hypochlorite and recognized not only “its exceptional antiseptic qualities but also the ability of hypochlorite to debride wounds.” See McDonnell, K. J., et al., “Dakin's Solution Revisited,” The American Journal of Orthopedics, July, 1997, pp. 471-3. Sodium hypochlorite solution in succeeding years became known in the medical community as “Dakin's Solution” and was known for its ability to destroy infection causing microorganisms.
  • While Dakin's solution has been a mainstay in topical antisepsis for almost 90 years, it has fallen into disuse in recent years because of reports of chemical trauma and cytotoxicity as ascertained by in-vitro laboratory tissue culture investigations. In particular, several studies have shown that the commonly used concentrations of sodium hypochlorite can inhibit host defense cells, such as macrophages, leucocytes and fibroblasts and thereby negatively interfere with the healing process. Moreover, laboratory studies have determined that dilute concentrations of Dakin's solution, such as 0.5%, 0.25% and 0.125% w/w, exhibit cytotoxic properties and can cause tissue damage. See e.g., Lineweaver W C, Howard R. Soucy D, et al., “Topical Antimicrobial Toxicity,” Arch Surg, 120:267-270, 1985; Kozol, R. A., et al., “Effects of Sodium Hypochlorite Solution (Dakin's Solution) on Cells of the Wound Module,” Arch Surg, 123:420-423 (1988). It is known that Dakin's solution exhibited cytotoxic properties that inhibited the wound healing process and impaired the host defense mechanism.
  • Dakin's solution in all concentrations is considered osmotically hypotonic, i.e., it can induce endoosmosis (swelling of tissue and blood cells by an increase in intracellular hydrostatic pressure) possibly causing local tissue stress and edema. Moreover, Dakin's solution diminishes rapidly in antimicrobial effectiveness and chemical activity over the course of its 30 day shelf life limiting its commercial availability to local or hospital pharmacies where it is made fresh to ensure potency. Further, when it is applied topically, it demonstrates a brief duration of action thereby requiring repeated applications to achieve unbroken antisepsis at the wound or burn site.
  • Based on the work of Lineweaver and others, the use of antiseptic solutions in wounds was discouraged in favor of isotonic saline solution (0.9% sodium chloride) for wound cleansing. Moreover, the institution of parenteral antibiotics for clinically infected wounds became the standard treatment protocol for all wounds. However, it was noted in the years following this protocol recommendation that isotonic or normal saline was ineffective in reducing wound bioburden (concentration of microorganisms per gram of tissue), a pre-infection state, or treating actual wound infection. Wound bioburden, as noted by Dow, G., et al., “Infection in Chronic Wounds: Controversies in Diagnosis and Treatment,” Ostomy/Wound Management, 45(8):23-40 (1999), demonstrated a direct link between bacterial wound bioburden and subsequent healing. Quantitatively, it has been shown that open wounds can maintain a bioburden of approximately 105 microorganisms without the clinical manifestations of infection. Bioburden of greater than 105 represent a significant challenge for local tissue defenses in the wound environment. A clinical wound infection usually results when 106 or more microorganisms per gram of tissue. As a consequence of these studies, the reduction of wound bioburden became a goal of wound therapy.
  • The emergence of bacterial resistance to a battery of previously effective antibiotic agents, coupled with an inadequate spectrum of action, and ineffective treatment outcomes, exposed the Achilles heel of antibiotics. Subsequently, topical antiseptics and antimicrobials once again emerged as powerful tools in infection control and wound care.
  • Prior art antiseptics or disinfectants containing chlorine are typically unsatisfactory for topical applications. Common hypochlorite solutions (bleach) are usually produced by bubbling chlorine in a concentrated solution of sodium hydroxide. Bleach solutions require high concentrations of caustic soda in order to remain stable and avoid decomposition resulting in a high pH that is injurious to skin and wound tissue. Other commonly used antiseptic agents such as Povidone iodine 10%, Hydrogen Peroxide 3% and Acetic Acid 0.25% all exhibit cytotoxic properties or inhibit neodermal formation.
  • Thus, there is a need for a composition that overcomes the deficiencies of antiseptics, such as Dakin's solution or other chlorine containing disinfectants.
  • SUMMARY
  • According to various aspects of the disclosure, there is provided a gel composition comprising a sodium hypochlorite solution; at least one viscosity-enhancing agent; and at least one electrolyte.
  • According to various aspects of the disclosure, there is provided a method of topically disinfecting a substrate comprising applying to the substrate an effective amount of a composition comprising a sodium hypochlorite solution; at least one viscosity-enhancing agent; and at least one electrolyte.
  • According to various aspects of the disclosure, there is provided a method of treating a topical infection comprising applying to a patient in need thereof an effective amount of a disinfectant composition comprising a sodium hypochlorite solution; at least one viscosity-enhancing agent; and at least one electrolyte to the infected area and/or the surrounding infected area.
  • According to various aspects of the disclosure, there is provided a method of treating a heavily contaminated or infected wound comprising applying to a patient in need thereof an effective amount of a composition comprising a sodium hypochlorite solution; at least one viscosity-enhancing agent; and at least one electrolyte to the contaminated or infected wound and/or the surrounding contaminated or infected area.
  • According to various aspects of the disclosure, there is provided a method of disinfecting an intact skin site prior to a surgical or invasive procedure comprising applying to a patient in need thereof an effective amount of a composition comprising a sodium hypochlorite solution; at least one viscosity-enhancing agent; and at least one electrolyte.
  • According to various aspects of the disclosure, there is provided a method for making a gel composition comprising combining at least one viscosity-enhancing agent with water; combining sodium hypochlorite with USP purified water; combining the sodium hypochlorite solution from (b) with the viscosity-enhancing solution from (a) to form a thickened solution; and combining at least one electrolyte with the thickened solution to form the gel composition.
  • It is to be understood that both the foregoing general description and the following description of various embodiments are exemplary and explanatory only and are not restrictive.
  • DESCRIPTION OF VARIOUS EMBODIMENTS
  • The disclosed composition can be safe and effective, broad spectrum, topical agents with at least one of the following properties: bacteriocidal, fungicidal and virucidal properties. Moreover, the composition can be in the form of a biologically compatible, non-traumatizing and non-cytotoxic, thixotropic, aqueous gel. The disclosed composition can also embody an osmotic potential thereby rendering it isotonic.
  • The disclosed composition can provide a method for treating skin sites or wounds that harbor infection-causing microorganisms. The composition can interfere with the microorganisms' reproductive mechanisms. This has the effect of inhibiting their multiplication and/or causing their death. The composition can therefore prevent and/or treat infectious disease without suppressing host defenses and/or exhibiting cytotoxic properties. The composition disclosed herein can also absorb wound exudates and other serosanguineous fluids that support the growth of pathogenic microorganisms, as well as cause the maceration of the skin around the wound margin that can retard healing. Moreover, the disclosed composition can also provide a method for maintaining the peripheral area around endogenous devices, such as intravenous and urinary indwelling catheters and/or any medical device that breaches the skin, vascular system or urinary tract free of infectious microorganisms.
  • The disclosed composition can also reduce the numbers of microorganisms that constitute a preinfection state (wound bioburden) to host manageable levels so that a natural sequence of wound healing can occur. Moreover, the composition can provide a sustained duration of antimicrobial action and to assist in maintaining a moist wound environment.
  • The disclosed composition can comprise a sodium hypochlorite solution, at least one viscosity-enhancing agent, and at least one electrolyte. The composition can maintain a useful shelf-life of at least 2 years.
  • The sodium hypochlorite solution can be prepared by any method known to one of ordinary skill in the art. In an embodiment, the sodium hypochlorite solution can be prepared by mixing commercially available sodium hypochlorite with USP purified water. For example, a concentration from about 5% to about 18%, for example from about 7% to about 15%, and as a further example from about 9% to about 13% by weight of commercially available sodium hypochlorite can be dispersed in USP purified water so that the resultant sodium hypochlorite solution comprises from about 0.0125% to about 1%, for example from about 0.1% to about 0.8%, by weight of sodium hypochlorite. Commercially available sodium hypochlorite can be available from Spectrum Chemical, Gardena, Calif. In another embodiment, the sodium hypochlorite solution is not prepared by partial electrolysis of a sodium chloride solution.
  • The composition disclosed herein can also comprise at least one viscosity-enhancing agent. The term “viscosity-enhancing agent” refers to any agent that, when applied in various concentrations in an aqueous medium, results in the formation of stable hydrogels that exhibit thixotropic properties. The at least one viscosity-enhancing agent can be chosen from natural clay and synthetic clay. In an embodiment, the hydrogel viscosity can be achieved by the use of an entirely synthetic mineral which is akin to the natural clay mineral hectorite in structure and composition. Unlike natural clay, a synthetic mineral is typically free of impurities yet can be equal in structure to natural hectorite. One such synthetic mineral is listed in the American Chemical Society's Chemical Abstracts Service (CAS) under the name sodium lithium magnesium silicate (Registration No. 53320-86-8) and in the Cosmetic, toiletries and Fragrance Association (CTFA) dictionary as sodium magnesium silicate. This synthetic mineral is sold commercially under the trade name LAPONITE®, a registered trademark of Southern Clay Products, Inc., Gonzales, Tex. Other non-limiting examples of the at least one viscosity-enhancing agent include magnesium aluminum silicates, smectite clays, and an amorphous clay mineral, such as allophone; two-layer type crystalline clay minerals, such as equidimensional crystal, kaolinite, and nacarite; elongate crystals, such as halloysites; three-layer type crystalline clay minerals, such as sodium montmorillonite, calcium montmorillonite, sauconite, vermiculite, nontronite, saponite, hectorite, and bentonite; chain structure crystalline clay minerals, such as attapulgite, sepiolite, and palygorskite; and mixtures thereof.
  • Two-layer type crystalline clay minerals can be sheet structures composed of units of one layer of silica and one layer of alumina octahedrons. Three-layer type crystalline clay minerals can be sheet structures composed of two layers of silica tetrahedrons and one central dioctahedral or trioctahedral layer. The chain structure crystalline clay minerals are hornblende-like chains of silica tetrahedrons linked together by octahedral groups of oxygen and hydroxyls containing aluminum and magnesium atoms.
  • In an embodiment, the at least one viscosity-enhancing agent can conform to the empirical formula Na0.7+((Si8Mg5.5Li0.3)O20(OH4))−0.7. The at least one viscosity-enhancing agent can serve as the gel matrix once ionic bonding has been completed.
  • The at least one viscosity-enhancing agent can be present in the composition in any desired or effective amount, such as from about 0.1% to about 10%, for example from about 0.5% to about 8%, and, as a further example, from about 1% to about 5% by weight with respect to the total weight of the composition. By varying the concentration of the at least one viscosity-enhancing agent, the gel composition can have consistencies that range from a heavy liquid to a thick, slightly cloudy gel.
  • Without being limited to any particular theory, it is believed that the swelling properties of the natural and synthetic clay minerals permit colloidal particles to form upon hydration. These colloidal particles can exhibit repulsive electrical surface charges, which can then be able to maintain a uniform suspension in solution. With the addition of an ionic compound, such as, for example, USP sodium chloride, USP potassium chloride, to the colloidal suspension, the repulsive particle charges can be reduced significantly, allowing the formation of a viscous, aqueous gel with rheologocial characteristics that can be typical of the clay mineral used. The formed gel can demonstrate at least one property such as the flow properties and the rheological behavior classically termed thixotropic, wherein a semi-solid gel can be induced by shaking or stirring, to become a sol (a thin liquid) and revert once again to a semi-solid gel upon standing.
  • In an embodiment, at least one organic modifier can be combined with the at least one viscosity-enhancing agent in order to realize the best properties of both. The at least one viscosity-enhancing agent and the at least one organic modifier can be used in a combination, such as an approximate ratio of about 4 parts of at least one viscosity-enhancing agent to about 1 part of at least one organic modifier. The at least one organic modifier can generally be cellulosic in nature, and can typically be used in the art to form thixotropic gels. Non-limiting examples of the at least one organic modifier include hydroxypropyl methyl cellulose, guar hydroxypropyl trimonium chloride, carbomer, xanthan gum, polyethylene glycol (PEG) block polymers, and polyvinylpyrrolidone.
  • The composition disclosed herein can also comprise at least one electrolyte. The at least one electrolyte can decrease or increase the ionic bond strength of the at least one viscosity-enhancing agent. In various embodiments, the at least one electrolyte is different from the sodium hypochlorite solution.
  • In various embodiments, the at least one electrolyte can be chosen from USP sodium chloride, NF hydrochloric acid, and USP citric acid. Other compounds, including alkali metal and alkali earth metal salts that dissociate into electrolytes such as the salts of potassium, magnesium, and calcium can also be used to initiate ionic bonding in the formation of thixotropic gels. Alternative electrolytes can produce gels with properties equivalent to those utilizing USP sodium chloride.
  • The at least one electrolyte can be present in the composition in any desired or effective amount, such as from about 0.01% to about 10%, for example, from about 0.1% to about 5%, and as a further example from about 1% to about 3% by weight with respect to the total weight of the composition.
  • The gel composition can have a wide variety of uses, including the effective treatment of topical bacterial and fungal infections, the treatment of heavily contaminated or infected wounds, and the preparation of an intact skin site prior to a surgical or invasive procedure.
  • A topical infection can be understood by those of ordinary skill in the art to refer generally to a minor infection, bacterial and/or fungal in nature, which can be typically superficial and localized.
  • A heavily contaminated wound can be understood by those of ordinary skill in the art to mean a wound that is heavily contaminated by micro-organisms, but not clinically infected. Such wounds can be often characterized by a prolonged period of inflammation, as well as a delay in wound healing or repair. Heavily infected wounds can be understood by those of ordinary skill in the art to mean wounds with a bioburden greater than 105 microorganisms per gram of tissue.
  • The rheological characteristics of thixotrophy, in which the apparent viscosity decreases as the system is disturbed by stirring or shaking and then reverses during periods of dormancy, can be useful in the administration and use of the composition described herein. The ability to apply a product to the skin with the use of simple delivery devices such as pump sprayers and squeeze tubes can eliminate the characteristic disadvantages of dispensing thin liquids and thick gels, where thin liquids cannot be contained at the treatment site and permanently thick gels cannot be easily dispensed. The rheological phase shift from gel to sol to gel can provide product administration latitude.
  • EXAMPLES
  • The following examples are illustrative and are non-limiting to the present teachings.
  • Manufacturing Method for Gel Composition
  • 0.1% to 10% w/w Laponite® was slowly added to USP purified water under vigorous agitation and mixed until the Laponite® was fully hydrated and a uniform, viscous liquid formed and appeared clear.
  • A sodium hypochlorite solution in a concentration from 5% to 18% was dispersed in an aliquat of USP purified water under vigorous agitation and mixed until completely dissolved to achieve a final concentration in the range of 0.0125% to 1% w/w.
  • 0.01% to 10% w/w of USP sodium chloride was very slowly added to the Laponite® and sodium hypochlorite mixture under continuous and vigorous agitation. Viscosity of the mixture increased immediately and the final composition formed a clear to slightly hazy, thick, semi-solid hydrogel.
  • For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing quantities, percentages or proportions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
  • Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Moreover, all ranges disclosed herein are to be understood to encompass any and all subranges subsumed therein. For example, a range of “less than 10” includes any and all subranges between (and including) the minimum value of zero and the maximum value of 10, that is, any and all subranges having a minimum value of equal to or greater than zero and a maximum value of equal to or less than 10, e.g., 1 to 5.
  • It is noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the,” include plural referents unless expressly and unequivocally limited to one referent. Thus, for example, reference to “an electrolyte” includes two or more different electrolytes. As used herein, the term “include” and its grammatical variants are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that can be substituted or added to the listed items.
  • The references cited herein are incorporated by reference in their entirety.
  • It will be apparent to those skilled in the art that various modifications and variations can be made to various embodiments described herein without departing from the spirit or scope of the present teachings. Thus, it is intended that the various embodiments described herein cover other modifications and variations within the scope of the appended claims and their equivalents.

Claims (18)

1. A gel composition comprising:
(a) a sodium hypochlorite solution that is not prepared by the partial electrolysis of a sodium chloride solution;
(b) at least one viscosity-enhancing agent; and
(c) at least one electrolyte.
2. The composition of claim 1, wherein the sodium hypochlorite solution comprises sodium hypochlorite in a concentration from about 5% to about 18% by weight of the solution and USP purified water.
3. The composition of claim 1, wherein the sodium hypochlorite is present in the gel composition in an amount ranging from about 0.0125% to about 1% by weight with respect to the total weight of the gel composition.
4. The composition of claim 3, wherein the sodium hypochlorite is present in the gel composition in an amount ranging from about 0.1% to about 0.8% by weight with respect to the total weight of the gel composition.
5. The composition of claim 1, wherein the at least one viscosity-enhancing agent is chosen from natural clay and synthetic clay.
6. The composition of claim 5, wherein the at least one viscosity-enhancing agent is a synthetic clay.
7. The composition of claim 1, wherein the at least one viscosity-enhancing agent further comprises at least one organic modifier.
8. The composition of claim 1, wherein the at least one viscosity-enhancing agent is present in the composition in an amount ranging from about 0.1 to about 10% by weight relative to the total weight of the composition.
9. The composition of claim 1, wherein the at least one viscosity-enhancing agent is chosen from magnesium aluminum silicates, smectite clays, allophone, kaolinite, nacarite, halloysites, sodium montmorillonite, calcium montmorillonite, sauconite, vermiculite, nontronite, saponite, hectorite, bentonite, attapulgite, sepiolite, palygorskite, and mixtures thereof.
10. The composition of claim 1, wherein the at least one electrolyte is present in the composition in an amount ranging from about 0.01 to about 10% by weight relative to the total weight of the composition.
11. The composition of claim 1, wherein the at least one electrolyte is chosen from USP sodium chloride, USP citric acid, and NF hydrochloric acid.
12. A method of topically disinfecting a substrate comprising applying to the substrate an effective amount of a composition comprising a sodium hypochlorite solution that is not prepared by the partial electrolysis of a sodium chloride solution; at least one viscosity-enhancing agent; and at least one electrolyte.
13. The method of claim 12, wherein the substrate is skin.
14. The method of claim 12, wherein the substrate is a wound.
15. A method of treating a topical infection comprising applying to a patient in need thereof an effective amount of a disinfectant composition comprising a sodium hypochlorite solution that is not prepared by the partial electrolysis of a sodium chloride solution; at least one viscosity-enhancing agent; and at least one electrolyte to the infected area and/or the surrounding infected area.
16. A method of treating a heavily contaminated or infected wound comprising applying to a patient in need thereof an effective amount of a composition according to claim 1 to the contaminated or infected wound and/or the surrounding contaminated or infected area.
17. A method of disinfecting an intact skin site prior to a surgical or invasive procedure comprising applying to a patient in need thereof an effective amount of a composition according to claim 1.
18. A method for making a gel composition comprising:
(a) combining at least one viscosity-enhancing agent with water;
(b) combining sodium hypochlorite with USP purified water;
(c) combining the sodium hypochlorite solution, which is not prepared by the partial electrolysis of a sodium chloride solution, from (b) with the viscosity-enhancing solution from (a) to form a thickened solution; and
(d) combining at least one electrolyte with the thickened solution to form the gel composition.
US11/114,148 2005-04-26 2005-04-26 Sodium hypochlorite gel composition Abandoned US20060241002A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/114,148 US20060241002A1 (en) 2005-04-26 2005-04-26 Sodium hypochlorite gel composition
CA2544383A CA2544383C (en) 2005-04-26 2006-04-18 Sodium hypochlorite gel composition
US11/562,691 US7622434B2 (en) 2005-04-26 2006-11-22 Sodium hypochlorite gel composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/114,148 US20060241002A1 (en) 2005-04-26 2005-04-26 Sodium hypochlorite gel composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/562,691 Continuation-In-Part US7622434B2 (en) 2005-04-26 2006-11-22 Sodium hypochlorite gel composition

Publications (1)

Publication Number Publication Date
US20060241002A1 true US20060241002A1 (en) 2006-10-26

Family

ID=37187684

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/114,148 Abandoned US20060241002A1 (en) 2005-04-26 2005-04-26 Sodium hypochlorite gel composition
US11/562,691 Active 2027-05-24 US7622434B2 (en) 2005-04-26 2006-11-22 Sodium hypochlorite gel composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/562,691 Active 2027-05-24 US7622434B2 (en) 2005-04-26 2006-11-22 Sodium hypochlorite gel composition

Country Status (2)

Country Link
US (2) US20060241002A1 (en)
CA (1) CA2544383C (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007121083A2 (en) * 2006-04-18 2007-10-25 The Clorox Company Thickened dilute hypochlorite
DE102007022994A1 (en) * 2007-05-15 2008-11-20 Actides Gmbh Disinfectants based on electrochemically activated water / electrolyte solutions, process for their preparation and use thereof
US20090181107A1 (en) * 1999-08-06 2009-07-16 Alan Buckley Solution having biocidal activity
WO2010079487A3 (en) * 2009-01-07 2010-09-10 Israel Institute For Biological Research Compositions for decontamination
WO2011014809A1 (en) 2009-07-30 2011-02-03 Oculus Innovative Sciences, Inc. Hydrogel formulation comprising oxidative reductive potential water
US8840873B2 (en) 2005-03-23 2014-09-23 Oculus Innovative Sciences, Inc. Method of treating second and third degree burns using oxidative reductive potential water solution
WO2014154818A1 (en) * 2013-03-29 2014-10-02 Commissariat à l'énergie atomique et aux énergies alternatives Oxidizing alkaline biodecontamination gel and surface biodecontamination method using said gel
US8871278B2 (en) 2011-03-18 2014-10-28 Puricore, Inc. Stabilized hypohalous acid solutions
US9381214B2 (en) 2011-03-18 2016-07-05 Puricore, Inc. Methods for treating skin irritation
US9782434B2 (en) 2006-01-20 2017-10-10 Sonoma Pharmaceuticals, Inc. Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
CN109418289A (en) * 2017-09-05 2019-03-05 上海利康消毒高科技有限公司 A kind of sodium hypochlorite gel and preparation method thereof
US10342825B2 (en) 2009-06-15 2019-07-09 Sonoma Pharmaceuticals, Inc. Solution containing hypochlorous acid and methods of using same
WO2020069771A1 (en) * 2018-10-05 2020-04-09 Sanixtreme Gmbh & Co Kg Gel, in particular for use in a wound treatment agent
CN111567518A (en) * 2020-05-27 2020-08-25 山东省科学院能源研究所 Gel-like sodium hypochlorite disinfectant and preparation method and application thereof
CN112584703A (en) * 2018-07-31 2021-03-30 拜耳公司 Thickener combinations for agrochemical (crop protection) formulations with high salt content
US11452778B2 (en) 2011-03-18 2022-09-27 Urgo Us, Inc. Stabilized hypohalous acid solutions
CN115624033A (en) * 2022-11-07 2023-01-20 传化集团有限公司日用品分公司 Stable high-available-chlorine-content disinfection gel and preparation method thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120148516A1 (en) * 2010-12-10 2012-06-14 Precision Dermatology, Inc. Tandem Hypochlorite-Barrier Repair Therapy for the Treatment of Eczema
WO2015143399A1 (en) * 2014-03-20 2015-09-24 Eberting Cheryl Lee Compositions for the treatment of dermatological diseases and disorders
WO2016202907A1 (en) * 2015-06-16 2016-12-22 Straumann Holding Ag Two-component system
WO2017127452A1 (en) * 2016-01-19 2017-07-27 Reoxcyn Discoveries Group, Inc. Hypochlorite formulations for wound healing
US9474768B1 (en) 2016-05-18 2016-10-25 Reoxcyn Discoveries Group, Inc. Lubricant formulations
US11857674B2 (en) 2016-05-18 2024-01-02 Reoxcyn, Llc Lubricant formulations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666679A (en) * 1968-08-02 1972-05-30 Chemed Corp Chlorine stable powder gelling composition
US4035483A (en) * 1973-05-29 1977-07-12 John Bunyan Antiseptic and non-toxic substance and a method of making the same
US5016228A (en) * 1986-03-19 1991-05-14 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Sonar transducers
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US6207201B1 (en) * 1993-06-03 2001-03-27 Amuchina International, Inc. Sodium hypochlorite based disinfectant and sterilizer for medical-surgical instruments
US6333054B1 (en) * 1999-10-21 2001-12-25 Amuchina S.P.A. Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015228A (en) 1989-06-05 1991-05-14 Eastman Kodak Company Sterilizing dressing device and method for skin puncture
US6001141A (en) 1996-11-12 1999-12-14 Ethyl Petroleum Additives, Ltd. Fuel additive
DE19715062C2 (en) 1997-04-11 2000-11-23 Daimler Chrysler Ag Process for applying a corrosion-protective adhesive layer to a metallic substrate
US6750183B2 (en) 2000-12-22 2004-06-15 Infineum International Ltd. Lubricating oil composition
US6748905B2 (en) 2002-03-04 2004-06-15 The Lubrizol Corporation Process for reducing engine wear in the operation of an internal combustion engine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666679A (en) * 1968-08-02 1972-05-30 Chemed Corp Chlorine stable powder gelling composition
US4035483A (en) * 1973-05-29 1977-07-12 John Bunyan Antiseptic and non-toxic substance and a method of making the same
US5016228A (en) * 1986-03-19 1991-05-14 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Sonar transducers
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US6207201B1 (en) * 1993-06-03 2001-03-27 Amuchina International, Inc. Sodium hypochlorite based disinfectant and sterilizer for medical-surgical instruments
US6333054B1 (en) * 1999-10-21 2001-12-25 Amuchina S.P.A. Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181107A1 (en) * 1999-08-06 2009-07-16 Alan Buckley Solution having biocidal activity
US8840873B2 (en) 2005-03-23 2014-09-23 Oculus Innovative Sciences, Inc. Method of treating second and third degree burns using oxidative reductive potential water solution
US9782434B2 (en) 2006-01-20 2017-10-10 Sonoma Pharmaceuticals, Inc. Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
WO2007121083A2 (en) * 2006-04-18 2007-10-25 The Clorox Company Thickened dilute hypochlorite
WO2007121083A3 (en) * 2006-04-18 2008-08-21 Clorox Co Thickened dilute hypochlorite
DE102007022994A1 (en) * 2007-05-15 2008-11-20 Actides Gmbh Disinfectants based on electrochemically activated water / electrolyte solutions, process for their preparation and use thereof
US20100310672A1 (en) * 2007-05-15 2010-12-09 Alfons Beltrup Disinfectant based on aqueous; hypochlorous acid (hoci)-containing solutions; method for the production thereof and use thereof
WO2010079487A3 (en) * 2009-01-07 2010-09-10 Israel Institute For Biological Research Compositions for decontamination
US10342825B2 (en) 2009-06-15 2019-07-09 Sonoma Pharmaceuticals, Inc. Solution containing hypochlorous acid and methods of using same
EP2459201A4 (en) * 2009-07-30 2014-03-12 Oculus Innovative Sciences Inc Hydrogel formulation comprising oxidative reductive potential water
AU2010278812B2 (en) * 2009-07-30 2016-12-01 Oculus Innovative Sciences, Inc. Hydrogel formulation comprising oxidative reductive potential water
WO2011014809A1 (en) 2009-07-30 2011-02-03 Oculus Innovative Sciences, Inc. Hydrogel formulation comprising oxidative reductive potential water
US10265341B2 (en) 2009-07-30 2019-04-23 Sonoma Pharmaceuticals, Inc. Hydrogel formulation comprising oxidative reductive potential water
CN102596207A (en) * 2009-07-30 2012-07-18 奥古露丝创新科学公司 Hydrogel formulation comprising oxidative reductive potential water
CN102596207B (en) * 2009-07-30 2018-04-24 索诺马制药公司 Hydrogel formulation comprising oxidation-reduction potential water
EP2459201A1 (en) * 2009-07-30 2012-06-06 Oculus Innovative Sciences, Inc. Hydrogel formulation comprising oxidative reductive potential water
US10034942B2 (en) 2011-03-18 2018-07-31 Realm Therapeutics, Inc. Stabilized hypohalous acid solutions
US9414584B2 (en) 2011-03-18 2016-08-16 Puricore, Inc. Stabilized hypohalous acid solutions
US9392787B2 (en) 2011-03-18 2016-07-19 Puricore, Inc. Stabilized hypohalous acid solutions
US9381214B2 (en) 2011-03-18 2016-07-05 Puricore, Inc. Methods for treating skin irritation
US9925217B2 (en) 2011-03-18 2018-03-27 Realm Therapeutics, Inc. Methods for treating inflammation associated with allergic reaction
US11452778B2 (en) 2011-03-18 2022-09-27 Urgo Us, Inc. Stabilized hypohalous acid solutions
US8871278B2 (en) 2011-03-18 2014-10-28 Puricore, Inc. Stabilized hypohalous acid solutions
US10702549B2 (en) 2011-03-18 2020-07-07 Urgo Us, Inc. Methods for treating skin irritation
US10576152B2 (en) 2011-03-18 2020-03-03 Urgo Us, Inc. Stabilized hypohalous acid solutions
US10251391B2 (en) 2013-03-29 2019-04-09 Commissariat A L'energie Atomique Et Aux Energies Alternatives Oxidizing alkaline biodecontamination gel and surface biodecontamination method using said gel
FR3003763A1 (en) * 2013-03-29 2014-10-03 Commissariat Energie Atomique ALKALINE OXIDIZING GEL FOR BIOLOGICAL DECONTAMINATION AND METHOD FOR BIOLOGICAL DECONTAMINATION OF SURFACES USING THE GEL.
WO2014154818A1 (en) * 2013-03-29 2014-10-02 Commissariat à l'énergie atomique et aux énergies alternatives Oxidizing alkaline biodecontamination gel and surface biodecontamination method using said gel
RU2669932C2 (en) * 2013-03-29 2018-10-17 Коммиссариат А Л'Энержи Атомик Э Оз Энержи Альтернатив Oxidizing alkaline biodecontamination gel and surface biodecontamination method using said gel
CN105263533A (en) * 2013-03-29 2016-01-20 原子能和替代能源委员会 Oxidizing alkaline biodecontamination gel and surface biodecontamination method using said gel
CN109418289A (en) * 2017-09-05 2019-03-05 上海利康消毒高科技有限公司 A kind of sodium hypochlorite gel and preparation method thereof
CN112584703A (en) * 2018-07-31 2021-03-30 拜耳公司 Thickener combinations for agrochemical (crop protection) formulations with high salt content
US20210289775A1 (en) * 2018-07-31 2021-09-23 Bayer Aktiengesellschaft Thickener combination for agrochemical (crop protection) formulations with high salt content
WO2020069771A1 (en) * 2018-10-05 2020-04-09 Sanixtreme Gmbh & Co Kg Gel, in particular for use in a wound treatment agent
CN111567518A (en) * 2020-05-27 2020-08-25 山东省科学院能源研究所 Gel-like sodium hypochlorite disinfectant and preparation method and application thereof
CN115624033A (en) * 2022-11-07 2023-01-20 传化集团有限公司日用品分公司 Stable high-available-chlorine-content disinfection gel and preparation method thereof

Also Published As

Publication number Publication date
US20070111911A1 (en) 2007-05-17
US7622434B2 (en) 2009-11-24
CA2544383A1 (en) 2006-10-26
CA2544383C (en) 2011-03-15

Similar Documents

Publication Publication Date Title
CA2544383C (en) Sodium hypochlorite gel composition
JP5546086B2 (en) Antibacterial hydrogel with thixotropic properties that is local and not cytotoxic
White An historical overview of the use of silver in wound management
Burks Povidone-iodine solution in wound treatment
EP2763665B1 (en) Antimicrobial compositions and methods employing same
RU2553363C2 (en) Antiseptic compositions and applications thereof
JP5112872B2 (en) Composition for treating wounds and burns
US20050266081A1 (en) Antimicrobial silver hydrogels
CN102335452A (en) Formula of functional dressing and preparation method thereof
SE1650162A1 (en) Antimicrobial and cleansing composition comprising a polymeric biguanide, EDTA, and surfactants.
US5035883A (en) Composition and method for treating human disorders susceptible to antimicrobial treatment
CA2926116C (en) Wound treatment composition
White The use of topical antimicrobials in wound bioburden control
Sethi A REVIEW ON MOLECULAR IODINE (I2) AND ITS TOPICAL APPLICATION ON SKIN AS AN ANTISEPTIC

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION